Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:GEMPNASDAQ:GNPXOTCMKTS:NRIFFNASDAQ:SNNAOTCMKTS:WIZP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGEMPGemphire Therapeutics$4.34+0.9%$4.97$0.24▼$1.49$64.54M2.82127,174 shs21,612 shsGNPXGenprex$2.98+10.0%$5.21$2.50▼$46.00$4.44M-0.5782,155 shs29,955 shsNRIFFNuvo Pharmaceuticals$0.75$0.30▼$0.87$8.52M1.577,337 shs3,000 shsSNNASienna Biopharmaceuticals$0.14$0.14$0.06▼$3.80$4.20M2.671.87 million shs13.32 million shsWIZPMawson Infrastructure Group$1.43-5.3%$1.86$0.07▼$1.45$695.44M1.77141,517 shs297,143 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGEMPGemphire Therapeutics-1.94%+4.62%-18.87%+30.30%+505.63%GNPXGenprex-0.36%-8.39%-39.06%-70.33%-92.66%NRIFFNuvo Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SNNASienna Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%WIZPMawson Infrastructure Group-4.43%+0.67%-5.63%-58.06%-49.83%Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGNPXGenprex4.2304 of 5 stars3.52.00.04.72.50.81.3NRIFFNuvo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASNNASienna BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGEMPGemphire TherapeuticsN/AN/AN/AN/AGNPXGenprex3.00Buy$10.00235.57% UpsideNRIFFNuvo PharmaceuticalsN/AN/AN/AN/ASNNASienna BiopharmaceuticalsN/AN/AN/AN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/ACurrent Analyst RatingsLatest NRIFF, SNNA, WIZP, GNPX, and GEMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2024GNPXGenprexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGEMPGemphire TherapeuticsN/AN/AN/AN/A$0.54 per shareN/AGNPXGenprexN/AN/AN/AN/A$18.55 per shareN/ANRIFFNuvo Pharmaceuticals$52.41M0.00N/A0.82$1.59 per share0.00SNNASienna BiopharmaceuticalsN/AN/AN/AN/A$1.27 per shareN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/A$0.03 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGEMPGemphire Therapeutics-$23.64MN/A0.00∞N/AN/A-419.70%-173.05%N/AGNPXGenprex-$23.74M-$24.80N/AN/AN/AN/A-194.71%-156.61%3/29/2024 (Estimated)NRIFFNuvo Pharmaceuticals$2.53M$0.0418.69N/AN/A-2.81%8.02%1.11%N/ASNNASienna Biopharmaceuticals-$73.47M-$3.59N/AN/AN/AN/A-177.36%-52.22%N/AWIZPMawson Infrastructure Group-$3.45M-$0.33N/AN/AN/AN/AN/A-85.32%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/ANRIFFNuvo PharmaceuticalsN/AN/AN/AN/AN/ASNNASienna BiopharmaceuticalsN/AN/AN/AN/AN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGEMPGemphire TherapeuticsN/A0.670.67GNPXGenprexN/A2.962.96NRIFFNuvo Pharmaceuticals5.272.672.11SNNASienna BiopharmaceuticalsN/A15.2715.27WIZPMawson Infrastructure GroupN/A1.131.13OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGEMPGemphire Therapeutics17.53%GNPXGenprex14.05%NRIFFNuvo PharmaceuticalsN/ASNNASienna Biopharmaceuticals17.36%WIZPMawson Infrastructure GroupN/AInsider OwnershipCompanyInsider OwnershipGEMPGemphire Therapeutics22.70%GNPXGenprex11.54%NRIFFNuvo PharmaceuticalsN/ASNNASienna Biopharmaceuticals27.20%WIZPMawson Infrastructure GroupN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableGEMPGemphire Therapeutics914.87 millionN/ANot OptionableGNPXGenprex311.49 million1.32 millionOptionableNRIFFNuvo Pharmaceuticals9911.40 millionN/ANot OptionableSNNASienna Biopharmaceuticals3930.91 millionN/ANot OptionableWIZPMawson Infrastructure Group2486.32 millionN/ANot OptionableNRIFF, SNNA, WIZP, GNPX, and GEMP HeadlinesSourceHeadlineMawson Infrastructure Group adds new customer at Midland bitcoin facilitybizjournals.com - December 20 at 11:39 AMMawson announces agreement for half of Midland bitcoin facility capacitybizjournals.com - October 19 at 5:32 PMMawson Infrastructure reports BTC production of 69 in July, down 3% M/Mseekingalpha.com - August 24 at 6:28 PMH.C. Wainwright Sticks to Its Buy Rating for Mawson Infrastructure Group (MIGI)markets.businessinsider.com - August 24 at 7:44 AMMawson Infrastructure Group Inc. Invites Submission of Indication of Interest for its BTC Hosting and HPC Co-location Servicestechnews.tmcnet.com - July 25 at 10:20 AMMawson Infrastructure Group Inc. Announces Monthly Operational Update for June 2023businesswire.com - July 19 at 10:01 AMMawson Infrastructure Group Inc. Announces Monthly Operational Update for May 2023technews.tmcnet.com - June 14 at 10:10 AMMawson Infrastructure Group names new president, CEObizjournals.com - May 22 at 12:56 PMWith Significant Increases In Megawatt Capacity And Bitcoin Production, Mawson Infrastructure Group (NASDAQ: MIGI) May Attract More Bitcoin Mining Investorsmsn.com - April 11 at 10:13 AMEarnings Outlook For Mawson Infrastructuremsn.com - November 12 at 8:40 PMBitcoin Miner CleanSpark Buys Mawson Site as Consolidation Risesfinance.yahoo.com - September 11 at 12:26 AMMawson Infrastructure Group Inc. To Sell Sandersville, Georgia Bitcoin Mining Facility including 6468 ASIC Bitcoin Miners To CleanSpark, Inc. For Up To $42.5 Millionbenzinga.com - September 9 at 10:20 AMWhy Bitcoin- And Ethereum-Related Stock CleanSpark Is Rising Todaybenzinga.com - September 9 at 10:20 AMMawson Infrastructure Group Inc. Announces July 2022 Bitcoin Self-Mining, Hosting Co-location, Energy Demand Response and Operational Updatefinance.yahoo.com - August 25 at 10:24 AMMawson Infrastructure Group Inc. Schedules Second Quarter Results Webcast for 5:30 p.m. ET on August 22, 2022benzinga.com - August 18 at 9:55 AMBitcoin Miner Mawson Infrastructure Produced 185 Bitcoin In Record-Breaking Maybitcoinmagazine.com - June 16 at 3:23 PMMawson to Develop New Bitcoin Mining Site in Texasfinance.yahoo.com - May 17 at 2:50 AMMawson Infrastructure Group Inc. Announces New 120 Megawatt Bitcoin Mining Facility in Texas, USAtmcnet.com - May 16 at 9:34 AMTexas Pacific Land Corporation, Mawson Infrastructure Group Inc., and JAI Energy Announce New Bitcoin Mining Venture in West Texastmcnet.com - May 16 at 9:34 AMMawson Infrastructure Group discusses Q3 highlights including Quinbrook renewable energy partnershipproactiveinvestors.com - December 14 at 11:45 PMAudacious Secures $20M Funding & Closes $3.1M Non-Brokered Private Placement Tranchebenzinga.com - December 11 at 11:01 PMEssential Investment? This REIT Believes in Cannabis-Related Real Estatebenzinga.com - December 9 at 6:25 PMSouth Dakota's Supreme Strikes Down Recreational Cannabis Vote, Overturning People's Willbenzinga.com - November 28 at 6:55 PM10 Weed Strains For People Who Like Cheesebenzinga.com - November 8 at 12:11 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsGemphire TherapeuticsNASDAQ:GEMPGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.GenprexNASDAQ:GNPXGenprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Nuvo PharmaceuticalsOTCMKTS:NRIFFNuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada.Sienna BiopharmaceuticalsNASDAQ:SNNASienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.Mawson Infrastructure GroupOTCMKTS:WIZPMawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company is headquartered in North Sydney, Australia. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.